Zacks Investment Research
26 Jun 2026, 15:45 UTC · 19w ago
Impact · against what's priced in
Nurix Therapeutics (NRIX) gains a significant catalyst through its Roche partnership, providing massive non-dilutive funding and validation for bexobrutideg. The $700 million upfront payment and total potential of $2.3 billion heavily outweigh the projected quarterly revenue decline.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Nurix Therapeutics (NRIX) entered an exclusive licensing and collaboration agreement with Roche to co-develop bexobrutideg (NX-5948).
More positive than 99% of claims this week
Nurix Therapeutics is entitled to a $700 million upfront payment and potential total payments of up to $2.3 billion from Roche.
So whatSignificant non-dilutive funding drastically improves the company's balance sheet and runway for R&D.
Continue reading
5 related stories
The exclusive licensing agreement with Roche for bexobrutideg provides $700 million upfront and up to $2.3 billion in total payments, drastically improving the company's financial runway.
Read from the article alone
No priced-in read yet
Roche has entered a strategic collaboration to co-develop and co-commercialize bexobrutideg for hematology, immunology, and neurology indications.
Read from the article alone
No priced-in read yet
The article mentions KROS only as a peer in the biomedical and genetics industry with no direct operational link to the Roche/Nurix deal.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More positive than 98% of claims this week
Nurix Therapeutics is expected to report a quarterly revenue decline of 67.5% year-over-year to $14.3 million.
More negative than 75% of claims this week
The consensus EPS estimate for Nurix Therapeutics has been revised 1.8% higher over the last 30 days.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Shares soared 16.4% following a high-value collaboration agreement with Roche.
More negative than 80% of ticker scores this week
Shares closed 4.7% lower in the last trading session and have returned -3.5% over the past month.
More positive than 69% of ticker scores this week
Entered into a strategic licensing and collaboration agreement to co-develop a lead pipeline candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
15h ago
More positive than 2% of relationship scores this week
[mutual] Both companies are identified as belonging to the Zacks Medical - Biomedical and Genetics industry.
−8.4%
$9.54 vs $10.41 close before publication (Jun 25) · not market-adjusted
KROS chart →+16.5%
Price agrees with the score
$60.57 vs $51.98 close before publication (Jun 25) · not market-adjusted
RHHBY chart →−27.3%
Price is moving against the score
$16.33 vs $22.46 close before publication (Jun 25) · not market-adjusted
NRIX chart →
